SELLAS Life Sciences Group, Inc. Board of Directors

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Dr. Angelos M. Stergiou M.D., ScD h.c.

Dr. Angelos M. Stergiou M.D., ScD h.c.

Founder, President, CEO & Director

Mr. Andrew Elnatan

Mr. Andrew Elnatan

VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality

Dr. Dragan Cicic M.D., MBA

Dr. Dragan Cicic M.D., MBA

Senior Vice President of Clinical Development

Ms. Stacy E. Yeung

Ms. Stacy E. Yeung

VP, Associate General Counsel & Head of Compliance

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.